This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Stryker (SYK) Posts Upbeat Preliminary Sales Figure for Q4
by Zacks Equity Research
Stryker Corporation's (SYK) fourth quarter and 2017 preliminary net sales figures are encouraging, courtesy of balanced revenue growth in all business segments.
Stryker's Global Foothold Strong Amid Product Recall Issue
by Zacks Equity Research
Stryker (SYK) enjoys strong foothold in the European and Australian markets. On the flip side, the company witnesses lower demand for health care products.
Company News For Dec 8, 2017
by Zacks Equity Research
Companies In The News are: CONN,GEF,LULU,SYK,ENTL
Stryker (SYK) Up 4.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Stryker (SYK) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker (SYK) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
Stryker Corporation (SYK) saw its shares rise over 7% on the day after the company reported better-than-expected third-quarter results.
Top Stock Reports for Amgen, Comcast & McDonald's
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Comcast (CMCSA), and McDonald's (MCD).
MedTech Growing on Emerging Markets, M&A: Stocks to Buy
by Zacks Equity Research
Given the current lack of clarity, let???s concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation.
MedTech Stock Q3 Earnings Roster for Oct 26: BSX, RMD & More
by Zacks Equity Research
Investors are concerned about the Medical sector that saw a lot of struggle during the first nine months of the year, thanks to the political change and the ongoing policy-restructuring related battle.
Will Sage-Unit Recall Hurt Stryker's (SYK) Q3 Earnings?
by Zacks Equity Research
In August, Stryker (SYK) announced a voluntary recall of the Oral Care line-up, which was offered by the company's Sage-Products unit.
NuVasive's TLX Interbody System Gets Expanded FDA Approval
by Zacks Equity Research
NuVasive (NUVA) leaves no stone unturned to cash in on the rapidly-evolving spine market.